

FOR IMMEDIATE RELEASE
24th January 2006



Ipsat Therapies Completes €3M Financing Round and Strengthens Board of Directors

Helsinki, Finland (24th January 2006) -- Ipsat Therapies, a Finnish biopharmaceutical company with a novel approach to fighting hospital acquired infections and antibiotic resistance today announced that it closed a €3 million private placement with InnovationsKapital, Stockholm, Sweden. The Company will use the proceeds for research and development of its product portfolio, primarily P1A, a recombinant enzyme for the prevention of antibiotic-associated diarrhea, antibiotic resistance, and gut disturbance. Ipsat Therapies is also actively pursuing alliances with partners to expedite commercialization.

Dr Ulf Tossman, Investment Director at InnovationsKapital, will join the Board of Directors. Dr Tossman commented: "We are excited about Ipsat's approach to fighting antibiotic resistance. We see that the technology has got potential to significantly reduce the unwanted side effects of antibiotic treatment for the benefit of patients and society."

"We are pleased to add InnovationsKapital to complement our Finnish investor base" Dr Wolfgang Pieken, Executive Chairman of Ipsat Therapies commented. "This also confirms the attractiveness of Ipsat's concept and its high potential."

--ENDS--

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

Dr Wolfgang Pieken
Chairman of the Board
Ipsat Therapies
Viikinkaari 4,
FIN-00790 Helsinki
Finland
Tel: +49 1728 225 407
Email: wpieken@mac.com
www.ipsat-ther.com

Dr Ulf Tossman
Investment Director
InnovationsKapital
Birger Jarlsgatan 13
SE-11145 Stockholm
Sweden
Tel: +46 705 630 858
Email: ulf.tossman@innkap.se
www.innkap.se

NOTES TO EDITORS:

About Ipsat Therapies

Ipsat Therapies is committed to fighting infectious diseases and prolonging the life of antibiotics by preventing the development of secondary infections and anti-microbial resistance. Ipsat believes that such an approach will complement other efforts in infectious diseases where new antibiotic discovery has not kept pace with the increasing development of resistance to older agents. Founded in 1999 the Company is based in the Helsinki Business and Science Park.

Based on its proprietary position in using recombinant enzymes targeted to intestinal antibiotic residue to protect the microflora during antibiotic treatment, this novel approach has the potential to preserve colonization resistance to pathogen overgrowth while preventing the development of anti-microbial

resistance. Using its expertise in drug development and experience in commercialization, the Company is advancing its products through clinical trials. Phase IIa studies with the first product were carried out in 2004 and Phase IIb will commence in 2006. Patient groups most likely to benefit from these products are the elderly, the immunosuppressed, and those on chronic antibiotic treatment.

Additional information is available on Ipsat Therapies' web site at www.ipsat-ther.com

InnovationsKapital

InnovationsKapital was founded in 1994 and is a leading early stage venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in Gothenburg and Stockholm, is focused on Nordic investments within ICT and Healthcare & Life Sciences – dynamic sectors that are rapidly expanding and where Nordic research plays an important role. InnvationsKapital currently advises three venture funds aggregating EUR 200 million in committed capital. The capital is provided by highly reputable Swedish and international institutional investors.

Further information about InnovationsKapital can be found at www.innkap.se